NCT03092856View on ClinicalTrials.gov

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

July 19, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Clear Cell Renal Cell CarcinomaMetastatic Renal Cell CancerRecurrent Renal Cell CarcinomaStage IV Renal Cell Cancer
Interventions
BIOLOGICAL

Anti-OX40 Antibody PF-04518600

Given IV

DRUG

Axitinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo

Given IV

Trial Locations (10)

10065

Weill Cornell Medical College, New York- Presbyterian Hospital, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

22903

University of Virginia Cancer Center, Charlottesville

43210

Ohio State University Comprehensive Cancer Center, Columbus

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

66160

University of Kansas Cancer Center, Kansas City

90033

Los Angeles County-USC Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

92663

USC Norris Oncology/Hematology-Newport Beach, Newport Beach

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER